Articles tagged with Drug Development
Researchers at Moffitt Cancer Center have developed a groundbreaking synthesis method for producing withanolides, a class of compounds that inhibit cancer cell growth and induce cell death. The scalable production of these compounds will advance cancer research and treatment development, offering new hope for patients.
A Phase 1 clinical trial is underway to evaluate the safety and efficacy of an investigational monoclonal antibody targeting enterovirus D68 (EV-D68), a virus associated with severe respiratory and neurological diseases. The trial will assess the antibody's potency, duration of action, and optimal dose in healthy volunteers.
A new global definition of sarcopenia is proposed, aiming to unify research and clinical practice. The definition may help identify low muscle mass or strength in older people, increasing the risk of poor outcomes such as fragility and disability.
Double-membrane vesicles form five common shapes through spontaneous self-organization, offering insight into lipid body intricacies. The study's findings could inspire synthetic materials and bio-inspired drug delivery systems.
Lenacapavir has shown 100% efficacy as PrEP among cisgender women in a Phase 3 clinical trial. The twice-yearly injection offers improved feasibility of PrEP for those experiencing barriers to daily pill-taking. NIAID looks forward to additional data and regulatory decisions.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
Researchers have developed three new cellular models of myotonic dystrophy type 1 that accurately represent the clinical diversity of the disease. The models show great heterogeneity in genetic expansion and molecular alterations, making them suitable for studying pathophysiology and testing therapeutic options.
Researchers have developed a method to deliver drugs to specific areas of the body using ultrasound waves, triggering drug release from stable nanocarriers. The approach is made both safe and efficient for the first time, paving the way for clinical trials.
Researchers found that carrying just one copy of the Christchurch variant delayed cognitive decline and dementia in family members, with some showing lower levels of tau proteins. The study suggests potential benefits for drug development targeting this genetic pathway.
Researchers developed two clinical ageing clocks, PCAge and LinAge, that use blood tests, a urine test, and a health questionnaire to estimate future mortality risk. These clocks show significant predictive efficacy in characterising individual future ageing trajectories.
Ternarx aims to unlock the potential of targeted protein degrader (TPD) technology to treat hard-to-treat cancers like neuroblastoma and prostate cancer. The company will initially focus on developing new treatments for these diseases using novel TPD technology.
A Kobe University study finds that a new treatment for neuromyelitis optica spectrum disorder shifts the balance of immune cells, increasing anti-inflammatory signals. The discovery may enable clinicians to determine treatment effectiveness and move towards personalized medicine for autoimmune diseases.
Finnish researchers found that blocking the DUSP6 protein can significantly improve treatment outcomes in experimental models by preventing dormant breast cancer cells from waking up. This discovery provides new insights into breast cancer recurrence and offers a potential basis for effective combination therapy.
Researchers at the University of Michigan Health Rogel Cancer Center discovered that pediatric DIPG tumors have a distinct metabolic pathway that allows them to evade treatment. By inhibiting this pathway, radiation therapy became effective in killing cancer cells.
The study highlights the potential of omics research and AI tools to disentangle the molecular drivers of Alzheimer’s disease. Key findings include the identification of novel biomarkers for early detection and therapeutic targets, as well as the exploration of genetic factors contributing to AD risk and progression.
A new review paper explores the mechanistic links between peripheral vascular dysfunction, cerebral vascular dysfunction, and reduced brain health with aging. The study suggests that targeting fundamental aging mechanisms may be a promising strategy to reduce dementia risk.
The researchers developed a novel viral reporter system called HIV-Tocky, which allows for real-time visualization of HIV dynamics post-viral infection. This innovation provides crucial insights into HIV-1 latency mechanisms and establishes a foundation for developing eradication strategies.
Researchers at Northwestern University discovered an attenuated virus that can help eliminate cancer in mice and prevent future tumor development. The therapy works by raising 'red flags' on tumors to alert immune cells to attack them.
A University of Houston researcher has made a breakthrough discovery about the development of the heart in the womb, revealing that a certain gene deletion can cause a common type of heart muscle disease called left ventricular non-compaction.
The study reveals that the binding sites of USP28 and USP25 inhibitors are identical, leading to non-specific effects. Researchers now aim to develop precise inhibitors targeting either enzyme site to reduce side effects.
Researchers at the University of British Columbia have developed oral insulin drops that can be easily absorbed by the body, potentially replacing insulin injections. The drops contain a unique cell-penetrating peptide that helps insulin navigate through cells and reach the bloodstream quickly.
Researchers at the University of North Carolina's Gillings School of Global Public Health have developed a new oral antiviral drug, obeldesivir (GS-5245), which has shown efficacy in treating COVID-19 in mice. The study suggests that obeldesivir could be a promising tool in future pandemic preparedness.
A study from Michigan Medicine reveals a connection between neutrophil activation and severe cytokine release syndrome (CRS), a potentially life-threatening reaction to CAR T-Cell therapy. Researchers identified biomarkers of NETosis, a process in which neutrophils create webs that may contribute to CRS.
Researchers review Silibinin's efficacy in managing inflammation, a key factor in tumour development and aging. The molecule may reduce drug-related toxicity and increase therapeutic potential in integrated cancer therapies.
Researchers tested seven antibiotics in combination with various natural compounds, finding synergistic effects against multidrug-resistant bacteria. The study suggests combining antibiotics with plant extracts or phytochemicals could be a promising strategy to combat antimicrobial resistance.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
Researchers developed adhesive hydrogel coatings that eliminate fibrosis, a common issue with medical implants. The coatings bind devices to tissue and prevent the immune system from attacking them.
Weo electrolyzed water (WEW) has been shown to attenuate cellular senescence in both normal fibroblasts and breast cancer cells. The study found that WEW modulated markers of cellular senescence, inflammation, and stress response genes in a cell type-dependent manner.
Researchers have developed an AI algorithm that can track protein clumping under the microscope in real-time, revolutionizing the study of neurodegenerative disorders. The tool helps identify key characteristics of clumped proteins, which can lead to new therapies.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
Researchers at Ochsner Health have developed SRP-001, a novel medication that leverages unique biological mechanisms to alleviate pain without typical side effects. The first-in-human Phase 1 trial confirms SRP-001's safety and tolerability, paving the way for its progression to further clinical stages.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Researchers discovered a link between disrupted developmental dopamine signaling and autism spectrum disorder, highlighting the importance of studying neural development pathways. The study found that dopaminergic signaling disruptions led to neural circuit abnormalities and behavioral phenotypes reminiscent of autism in zebrafish larvae.
A KAUST team developed a simple approach to tackle CRISPR's deletion issue by targeting error-prone DNA repair pathways. By modulating specific genes, they reduced large deletions while enhancing homology-directed repair efficiency.
Researchers Polina A. Loseva and Vadim N. Gladyshev challenge the existing definition of human life, suggesting a new meaning for the 14-day stage in organismal life grounded in recent mechanistic advances and insights from aging studies. This stage defines the separation of soma from the germline and marks the boundary between rejuven...
Researchers have developed a new technique called molecular pixelation, which allows for the analysis of hundreds of proteins simultaneously in individual cells. This provides a more detailed picture of protein distribution and interactions, crucial for understanding cellular function and signaling.
Researchers at the University of Toronto have found a family of natural compounds that stall the unique metabolic process used by parasites to survive in the human gut. The discovery offers potential as new and more effective treatments for parasitic worm infections, which cause debilitating symptoms and developmental defects.
Scientists have found an effective treatment for spitting cobra snakebites by blocking one of the major dermonecrosis-causing toxins with varespladib. The study suggests that this repurposed drug can prevent tissue damage and may become a valuable treatment against black-necked and red spitting cobra venoms.
A Purdue University researcher has received a $2.4 million NIH grant to develop novel inhalation therapeutics for resistant lung infections, which have established resistance to antimicrobial drugs and affect over 2.8 million individuals annually in the US, resulting in more than 35,000 deaths.
Researchers at Sylvester Comprehensive Cancer Center have developed a nanoparticle that can penetrate the blood-brain barrier, potentially targeting both primary breast cancer tumors and brain metastases in one treatment. The method shows early promise in preclinical models, where it shrinks breast and brain tumors.
Researchers have developed a new anticoagulant with an on-off switch, providing rapid control of bleeding risks in surgery and blood clots. The supramolecular approach combines a tsetse fly protein with a synthetic peptide, allowing for the anticoagulant to be rapidly deactivated by introducing correctly matched strands of free PNA.
A new study from MIT researchers has found that many genes involved in drug metabolism follow a circadian rhythm, affecting how much of a drug is available and how effectively the body breaks it down. The study's findings have implications for developing better dosing schedules for existing drugs.
Scientists have identified a shared gene module in people with depression and cardiovascular disease, providing new markers for both conditions. The study found that genes involved in inflammation are associated with both diseases, explaining why they often occur together.
Researchers identified 35-63 proteins affecting severe COVID-19, hospitalization, SARS-COV2 infection, and 4-32 proteins for healthspan and lifespan. Novel proteins involved in inflammation, immunity, apoptosis and metabolism were also found.
Researchers at Weill Cornell Medicine have discovered a way to boost protective effects of sphingolipids in blood vessels, slowing the development and progression of coronary artery disease. The study suggests revising current views on ceramides' role in the disease, instead finding that their levels remain stable in endothelial cells.
Researchers assessed swimming performance and survival under stress to evaluate the effects of three compounds on health and lifespan in Caenorhabditis. The study found complex relationships among median lifespan, oxidative stress resistance, thermotolerance, and mobility vigor.
Researchers have discovered that rice bran-derived nanoparticles exhibit strong anticancer effects, selectively targeting cancer cells while sparing healthy tissue. The nanoparticles reduced tumor growth and inhibited metastatic cell growth in mice models.
Scientists at CNIC have identified mechanisms by which anthracyclines damage the hearts of cancer patients, leading to cardiac injury. The study suggests that a protein-enriched diet may prevent muscle atrophy caused by anthracycline chemotherapy.
A new study developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of cancer specimens in patients with non-small cell lung cancer. The models hold promise for identifying patients who may benefit from immunotherapy.
A study by researchers at Washington University School of Medicine has found that a drug used to treat epilepsy can prevent brain tumor formation and growth in mice with neurofibromatosis type 1 (NF1). The drug, lamotrigine, was shown to be effective at lower doses than those used for epilepsy, and its effects were lasting. The finding...
A new study by University of Waterloo researchers suggests that Canada will not reach the World Health Organization's goal of eliminating Hepatitis C by 2030. The main reason is the lack of harm-reduction strategies, which are crucial for reducing the transmission of the virus.
A new research project, PHOTOZYME, aims to develop photobiocatalytic tools to convert basic chemicals into chiral molecules. The project combines biocatalysis, photochemistry, and directed evolution to create sustainable molecular synthesis.
Researchers at the University of Eastern Finland have identified coregulator proteins as an alternative target to prevent drug resistance in prostate cancer. By inhibiting these proteins, the growth of drug-resistant cancer cells can be inhibited, and the activity of the glucocorticoid receptor can be limited.
A new statistical-modeling workflow can quickly identify molecular structures of products formed by chemical reactions, accelerating drug discovery and synthetic chemistry. The workflow also enables the analysis of unpurified reaction mixtures, reducing time spent on purification and characterization.
Researchers developed a breakthrough test to assess the enzymatic activity of glutathione peroxidase 4 (GPX4), a pivotal regulator of ferroptosis. The assay accurately measures GPX4 activity and extends its utility beyond GPX4, allowing for precise evaluation of other enzymes involved in ferroptosis regulation.
Researchers at Princeton University used language models to optimize partial genome sequences and create more effective mRNA vaccines. The model successfully generated hundreds of new sequences, validating its results through lab experiments, and outperforming benchmarks for vaccine development.
A Scripps Research team has uncovered a simple and inexpensive way to produce quaternary carbon molecules using an iron catalyst. This breakthrough could benefit drug developers by making molecules cheaper and easier to produce at small and large scales.
A recent study has identified a key component of the malaria parasite's invasion mechanism, revealing that it binds to a specific sugar called sialic acid on red blood cell surfaces. This discovery provides new insights into the parasite's adaptation to humans and offers potential targets for vaccine and drug development.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.